home · filing · 0001213900-25-003401
8-K
filed January 14, 2025, 6:59 PM ET
ticker RAPH
CIK 0001415397
leadership
confidence high
sentiment neutral
materiality 0.40
Raphael Pharmaceuticals appoints Ajay Kumar Dhadha as Director and Chairman, replacing Shlomo Pilo
Raphael Pharmaceutical Inc.
Board expanded by one seat; Ajay Kumar Dhadha appointed Director and Chairman effective January 8, 2025.
Dhadha, age 79, is a diamond dealer, founder/CEO of Shanti Gems (1982) Ltd., and Israel Diamond Exchange member.
No arrangement, transaction, or reportable relationship exists between Dhadha and the company under Item 404(a).
Board concluded Dhadha is qualified and independent; standard indemnification agreement to be entered.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-01-08
Filed January 14, 2025, 6:59 PM ET
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
Effective 2025-01-08
Successor Ajay Kumar Dhadha
Filed January 14, 2025, 6:59 PM ET
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ajay Kumar Dhadha was appointed as Director and Chairman at Raphael Pharmaceutical Inc..
Action appointed
Role Director and Chairman
Exact text from the filing
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Shlomo Pilo changed role as Chairman at Raphael Pharmaceutical Inc..
Action replaced
Role Chairman
Exact text from the filing
The Board also selected Mr. Dhadha to be Chairman of the Board, replacing Mr. Shlomo Pilo in such role.
View on SEC.gov
Source: SEC EDGAR
accession 0001213900-25-003401
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.